Business Description
This fund puts at least 80% of its money into publicly traded companies that earn half or more of their revenue from GLP-1 related products or services, as well as treatments for heart and metabolic conditions recognized by the CDC. The portfolio typically holds between 15 and 100 companies and is considered non-diversified, meaning it may concentrate its holdings more heavily than a standard fund.
